527 related articles for article (PubMed ID: 19499915)
1. In situ cross-linkable high molecular weight hyaluronan-bisphosphonate conjugate for localized delivery and cell-specific targeting: a hydrogel linked prodrug approach.
Varghese OP; Sun W; Hilborn J; Ossipov DA
J Am Chem Soc; 2009 Jul; 131(25):8781-3. PubMed ID: 19499915
[TBL] [Abstract][Full Text] [Related]
2. Fragmented hyaluronan is an autocrine chemokinetic motility factor supported by the HAS2-HYAL2/CD44 system on the plasma membrane.
Saito T; Kawana H; Azuma K; Toyoda A; Fujita H; Kitagawa M; Harigaya K
Int J Oncol; 2011 Nov; 39(5):1311-20. PubMed ID: 21743962
[TBL] [Abstract][Full Text] [Related]
3. The over-expression of HAS2, Hyal-2 and CD44 is implicated in the invasiveness of breast cancer.
Udabage L; Brownlee GR; Nilsson SK; Brown TJ
Exp Cell Res; 2005 Oct; 310(1):205-17. PubMed ID: 16125700
[TBL] [Abstract][Full Text] [Related]
4. Reticulated hyaluronan hydrogels: a model for examining cancer cell invasion in 3D.
David L; Dulong V; Le Cerf D; Chauzy C; Norris V; Delpech B; Lamacz M; Vannier JP
Matrix Biol; 2004 Jun; 23(3):183-93. PubMed ID: 15296946
[TBL] [Abstract][Full Text] [Related]
5. An insight on hyaluronic acid in drug targeting and drug delivery.
Yadav AK; Mishra P; Agrawal GP
J Drug Target; 2008 Feb; 16(2):91-107. PubMed ID: 18274931
[TBL] [Abstract][Full Text] [Related]
6. Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy.
Choi KY; Yoon HY; Kim JH; Bae SM; Park RW; Kang YM; Kim IS; Kwon IC; Choi K; Jeong SY; Kim K; Park JH
ACS Nano; 2011 Nov; 5(11):8591-9. PubMed ID: 21967065
[TBL] [Abstract][Full Text] [Related]
7. Hyaluronan as carrier of carboranes for tumor targeting in boron neutron capture therapy.
Meo CD; Panza L; Capitani D; Mannina L; Banzato A; Rondina M; Renier D; Rosato A; Crescenzi V
Biomacromolecules; 2007 Feb; 8(2):552-9. PubMed ID: 17291079
[TBL] [Abstract][Full Text] [Related]
8. Guided molecular missiles for tumor-targeting chemotherapy--case studies using the second-generation taxoids as warheads.
Ojima I
Acc Chem Res; 2008 Jan; 41(1):108-19. PubMed ID: 17663526
[TBL] [Abstract][Full Text] [Related]
9. In situ cross-linkable hydrogel of hyaluronan produced via copper-free click chemistry.
Takahashi A; Suzuki Y; Suhara T; Omichi K; Shimizu A; Hasegawa K; Kokudo N; Ohta S; Ito T
Biomacromolecules; 2013 Oct; 14(10):3581-8. PubMed ID: 24004342
[TBL] [Abstract][Full Text] [Related]
10. Hyaluronan-coated nanoparticles: the influence of the molecular weight on CD44-hyaluronan interactions and on the immune response.
Mizrahy S; Raz SR; Hasgaard M; Liu H; Soffer-Tsur N; Cohen K; Dvash R; Landsman-Milo D; Bremer MG; Moghimi SM; Peer D
J Control Release; 2011 Dec; 156(2):231-8. PubMed ID: 21745506
[TBL] [Abstract][Full Text] [Related]
11. The influence of hyaluronan-CD44 interaction on topoisomerase II activity and etoposide cytotoxicity in head and neck cancer.
Wang SJ; Peyrollier K; Bourguignon LY
Arch Otolaryngol Head Neck Surg; 2007 Mar; 133(3):281-8. PubMed ID: 17372087
[TBL] [Abstract][Full Text] [Related]
12. Hyaluronic acid-paclitaxel conjugate micelles: synthesis, characterization, and antitumor activity.
Lee H; Lee K; Park TG
Bioconjug Chem; 2008 Jun; 19(6):1319-25. PubMed ID: 18481885
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But.
Coradini D; Zorzet S; Rossin R; Scarlata I; Pellizzaro C; Turrin C; Bello M; Cantoni S; Speranza A; Sava G; Mazzi U; Perbellini A
Clin Cancer Res; 2004 Jul; 10(14):4822-30. PubMed ID: 15269158
[TBL] [Abstract][Full Text] [Related]
14. Cancer cell specific targeting of nanogels from acetylated hyaluronic acid with low molecular weight.
Park W; Kim KS; Bae BC; Kim YH; Na K
Eur J Pharm Sci; 2010 Jul; 40(4):367-75. PubMed ID: 20417709
[TBL] [Abstract][Full Text] [Related]
15. The magic glue hyaluronan and its eraser hyaluronidase: a biological overview.
Girish KS; Kemparaju K
Life Sci; 2007 May; 80(21):1921-43. PubMed ID: 17408700
[TBL] [Abstract][Full Text] [Related]
16. Lipoplexes targeting the CD44 hyaluronic acid receptor for efficient transfection of breast cancer cells.
Surace C; Arpicco S; Dufaÿ-Wojcicki A; Marsaud V; Bouclier C; Clay D; Cattel L; Renoir JM; Fattal E
Mol Pharm; 2009; 6(4):1062-73. PubMed ID: 19413341
[TBL] [Abstract][Full Text] [Related]
17. Novel types of carborane-carrier hyaluronan derivatives via "click chemistry".
Di Meo C; Panza L; Campo F; Capitani D; Mannina L; Banzato A; Rondina M; Rosato A; Crescenzi V
Macromol Biosci; 2008 Jul; 8(7):670-81. PubMed ID: 18412288
[TBL] [Abstract][Full Text] [Related]
18. Targeting hyaluronan interactions in malignant gliomas and their drug-resistant multipotent progenitors.
Gilg AG; Tye SL; Tolliver LB; Wheeler WG; Visconti RP; Duncan JD; Kostova FV; Bolds LN; Toole BP; Maria BL
Clin Cancer Res; 2008 Mar; 14(6):1804-13. PubMed ID: 18347183
[TBL] [Abstract][Full Text] [Related]
19. Bioresponsive hyaluronic acid-capped mesoporous silica nanoparticles for targeted drug delivery.
Chen Z; Li Z; Lin Y; Yin M; Ren J; Qu X
Chemistry; 2013 Jan; 19(5):1778-83. PubMed ID: 23303570
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonate-linked hyaluronic acid hydrogel sequesters and enzymatically releases active bone morphogenetic protein-2 for induction of osteogenic differentiation.
Hulsart-Billström G; Yuen PK; Marsell R; Hilborn J; Larsson S; Ossipov D
Biomacromolecules; 2013 Sep; 14(9):3055-63. PubMed ID: 23947433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
